N. Jane Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
N. Jane Taylor has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
- Anwar Roshanali Padhani
Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, England
28 shared publications - David J. Collins
Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
19 shared publications J. James Stirling
From the Department of Radiology (S.G., D.P., V.G.) and PET Centre (J.J.S., G.J.R.C.), Guy's and St Thomas' Hospitals NHS Foundation Trust, Level 1, Lambeth Wing, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH; Division of Imaging Sciences and Biomedical Engineering, King's College London, London, England (G.D., D.P., B.T., J.J.S., M.S., G.J.R.C., V.G.); and the Cancer Centre, Mount Vernon Hospital, Northwood, England (N.J.T., R.G.).
17 shared publications- Martin O. Leach
Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy & Imaging, The Institute of Cancer Research, London, SM2 5NG, UK
7 shared publications Andreas Makris
6 shared publications- Peter Hoskin
Mount Vernon Cancer Centre, Middlesex, United Kingdom
6 shared publications
Latest Publications
- Open Access
E xploratory study of using M agnetic resonance P rognostic I maging markers for R adiotherapy I n C ervix cancer (EMPIRIC): a prospective cohort study protocol
Introduction Radical chemoradiotherapy represents the gold standard for locally advanced cervical cancer. However, despite significant progress in improving local tumour control, distant relapse continues to impact overall survival. The development of predictive and prognostic biomarkers is consequently important to risk-stratify patients and identify populations at higher risk of poorer treatment response and survival outcomes. Exploratory study of using Magnetic resonance Prognostic Imaging markers for Radiotherapy In Cervix cancer (EMPIRIC) is a prospective exploratory cohort study, which aims to investigate the role of multiparametric functional MRI (fMRI) using diffusion-weighed imaging (DWI), dynamic contrast-enhanced (DCE) and blood oxygen level-dependent imaging (BOLD) MRI to assess treatment response and predict outcomes in patients undergoing radical chemoradiotherapy for cervical cancer. Methods and analysis The study aims to recruit 40 patients across a single-centre over 2 years. Patients undergo multiparametric fMRI (DWI, DCE and BOLD-MRI) at three time points: before, during and at the completion of external beam radiotherapy. Tissue and liquid biopsies are collected at diagnosis and post-treatment to identify potential biomarker correlates against fMRI. The primary outcome is to evaluate sensitivity and specificity of quantitative parameters derived from fMRI as predictors of progression-free survival at 2 years following radical chemoradiotherapy for cervical cancer. The secondary outcome is to investigate the roles of fMRI as predictors of overall survival at 2 years and tumour volume reduction across treatment. Statistical analyses using regression models and survival analyses are employed to evaluate the relationships between the derived parameters, treatment response and clinical outcomes. Ethics and dissemination The EMPIRIC study received ethical approval from the NHS Health Research Authority (HRA) on 14 February 2022 (protocol number RD2021-29). Confidentiality and data protection measures are strictly adhered to throughout the study. The findings of this study will be disseminated through peer-reviewed publications and scientific conferences, aiming to contribute to the growing body of evidence on the use of multiparametric MRI in cervical cancer management. Trial registration number NCT05532930.
Open AccessE xploratory study of using M agnetic resonance P rognostic I maging markers for R adiotherapy I n C ervix cancer (EMPIRIC): a prospective cohort study protocol
Introduction Radical chemoradiotherapy represents the gold standard for locally advanced cervical cancer. However, despite significant progress in improving local tumour control, distant relapse continues to impact overall survival. The development of predictive and prognostic biomarkers is consequently important to risk-stratify patients and identify populations at higher risk of poorer treatment response and survival outcomes. Exploratory study of using Magnetic resonance Prognostic Imaging markers for Radiotherapy In Cervix cancer (EMPIRIC) is a prospective exploratory cohort study, which aims to investigate the role of multiparametric functional MRI (fMRI) using diffusion-weighed imaging (DWI), dynamic contrast-enhanced (DCE) and blood oxygen level-dependent imaging (BOLD) MRI to assess treatment response and predict outcomes in patients undergoing radical chemoradiotherapy for cervical cancer. Methods and analysis The study aims to recruit 40 patients across a single-centre over 2 years. Patients undergo multiparametric fMRI (DWI, DCE and BOLD-MRI) at three time points: before, during and at the completion of external beam radiotherapy. Tissue and liquid biopsies are collected at diagnosis and post-treatment to identify potential biomarker correlates against fMRI. The primary outcome is to evaluate sensitivity and specificity of quantitative parameters derived from fMRI as predictors of progression-free survival at 2 years following radical chemoradiotherapy for cervical cancer. The secondary outcome is to investigate the roles of fMRI as predictors of overall survival at 2 years and tumour volume reduction across treatment. Statistical analyses using regression models and survival analyses are employed to evaluate the relationships between the derived parameters, treatment response and clinical outcomes. Ethics and dissemination The EMPIRIC study received ethical approval from the NHS Health Research Authority (HRA) on 14 February 2022 (protocol number RD2021-29). Confidentiality and data protection measures are strictly adhered to throughout the study. The findings of this study will be disseminated through peer-reviewed publications and scientific conferences, aiming to contribute to the growing body of evidence on the use of multiparametric MRI in cervical cancer management. Trial registration number NCT05532930.
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
Evaluation of Multiparametric Magnetic Resonance Imaging to assist Adaptive Radiotherapy in Prostate Cancer – an interim report
Initial results of a prostate cancer study investigating whether multiparametric MRI (MP-MRI), involving diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI, can predict or assess tumour response to radiotherapy (RT) and potentially support adaptive radiotherapy for high-risk patients. Adaptive radiotherapy is a treatment technique utilised to minimise radiation related toxicity. For some cancers it is possible to adapt radiotherapy according to physical changes that occur during treatment. This is not appropriate for prostate cancer treatment since observable changes are generally due to rectal movement, however it may be possible to use multiparametric MRI (MP-MRI) to measure treatment response.
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
Evaluation of Multiparametric Magnetic Resonance Imaging to assist Adaptive Radiotherapy in Prostate Cancer – an interim report
Initial results of a prostate cancer study investigating whether multiparametric MRI (MP-MRI), involving diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) MRI, can predict or assess tumour response to radiotherapy (RT) and potentially support adaptive radiotherapy for high-risk patients. Adaptive radiotherapy is a treatment technique utilised to minimise radiation related toxicity. For some cancers it is possible to adapt radiotherapy according to physical changes that occur during treatment. This is not appropriate for prostate cancer treatment since observable changes are generally due to rectal movement, however it may be possible to use multiparametric MRI (MP-MRI) to measure treatment response.
- Open Access
Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Introduction Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial. Methods and analysis The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer. Ethics and dissemination This study has been approved by the Yorkshire and The Humber—Bradford Leeds Research Ethics Committee (Reference: 21/YH/0305, IRAS: 297060, January 2022). The results will be presented in national and international conferences, published in peer-reviewed journals and will be communicated to relevant stakeholders. A plain English report will be shared with the study participants, patients’ organisations and media. Trial registration number ISRCTN 12238218 (Amy Ackroyd NIHR CPMS Team).
Open AccessReirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Introduction Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial. Methods and analysis The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer. Ethics and dissemination This study has been approved by the Yorkshire and The Humber—Bradford Leeds Research Ethics Committee (Reference: 21/YH/0305, IRAS: 297060, January 2022). The results will be presented in national and international conferences, published in peer-reviewed journals and will be communicated to relevant stakeholders. A plain English report will be shared with the study participants, patients’ organisations and media. Trial registration number ISRCTN 12238218 (Amy Ackroyd NIHR CPMS Team).
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1346-S1347
A new horizon-electromagnetic (EM) needle tip tracking to support mpMRI/US fusion transperineal prostate biopsies under local anaesthetia
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1346-S1347
A new horizon-electromagnetic (EM) needle tip tracking to support mpMRI/US fusion transperineal prostate biopsies under local anaesthetia
- Open Access
- 1 November 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 293 (2) , 374-383
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker
The apparent diffusion coefficient was a repeatable marker in a multicenter trial in advanced epithelial ovarian cancer across multivendor platforms, and is an indicator of progression-free surviva... Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary a...
- 1 November 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 293 (2) , 374-383
Open AccessDiffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker
The apparent diffusion coefficient was a repeatable marker in a multicenter trial in advanced epithelial ovarian cancer across multivendor platforms, and is an indicator of progression-free surviva... Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary a...
- Open Access
- 1 August 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 284 (2) , 552-561
Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features
First-order histogram parameters (mean, median, entropy) and model-based fractal parameters (fractal dimension mean, fractal dimension standard deviation) consistently demonstrated good repeatabili... Purpose To assess the day-to-day repeatability of global and local-regional magnetic resonance (MR) imaging texture features derived from primary rectal cancer. Materials and Methods After ethical ...
- 1 August 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 284 (2) , 552-561
Open AccessPrimary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features
First-order histogram parameters (mean, median, entropy) and model-based fractal parameters (fractal dimension mean, fractal dimension standard deviation) consistently demonstrated good repeatabili... Purpose To assess the day-to-day repeatability of global and local-regional magnetic resonance (MR) imaging texture features derived from primary rectal cancer. Materials and Methods After ethical ...
- Open Access
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S501-S502
PO-0906: Textural analysis of MR images to improve the characterisation of recurrent prostate cancer
- 1 May 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 123, S501-S502
Open AccessPO-0906: Textural analysis of MR images to improve the characterisation of recurrent prostate cancer
- 1 July 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1063) , 20150961
Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?
To evaluate the performance of six models of population Arterial Input Function (AIF) in the setting of primary breast cancer and neoadjuvant chemotherapy (NAC). The ability to fit patient DCE-MRI data, provide physiological plausible data and detect pathological response are assessed. Quantitative DCE-MRI parameters were calculated for 27 patients at baseline and after 2 cycles of NAC for 6 AIFs. Pathologic complete response (pCR) detection was compared to change in these parameters from a reproduction cohort of 12 patients using a Bland-Altman approach and receiver operator characteristic (ROC) analysis. There were fewer fit failures pre NAC for all models with the Modified Fritz-Hansen having the fewest pre NAC (3.6%) and post NAC (18.8%), contrasting with the Femoral Artery AIF (19.4% and 43.3% respectively). Median Ktrans values were greatest for the Weinmann function and also showed greatest reductions with treatment (-68%). Reproducibility (r) was the lowest for the Weinmann function (r = -49.7%) with the other AIFs ranging from r -27.8 to r -39.2%. Using the best performing AIF is essential to maximise the utility of quantitative DCE-MRI parameters in predicting response to NAC treatment. Applying our criteria the Modified Fritz-Hansen and Cosine Bolus approximated Parker AIF models performed best. The Fritz-Hansen and biexponential approximated Parker AIFs performed less well and the Weinmann and femoral artery AIFs are not recommended. We demonstrate that using the most appropriate Arterial Input Function (AIF) can aid successful prediction of response to neoadjuvant chemotherapy in breast cancer.
- 1 July 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1063) , 20150961
Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?
To evaluate the performance of six models of population Arterial Input Function (AIF) in the setting of primary breast cancer and neoadjuvant chemotherapy (NAC). The ability to fit patient DCE-MRI data, provide physiological plausible data and detect pathological response are assessed. Quantitative DCE-MRI parameters were calculated for 27 patients at baseline and after 2 cycles of NAC for 6 AIFs. Pathologic complete response (pCR) detection was compared to change in these parameters from a reproduction cohort of 12 patients using a Bland-Altman approach and receiver operator characteristic (ROC) analysis. There were fewer fit failures pre NAC for all models with the Modified Fritz-Hansen having the fewest pre NAC (3.6%) and post NAC (18.8%), contrasting with the Femoral Artery AIF (19.4% and 43.3% respectively). Median Ktrans values were greatest for the Weinmann function and also showed greatest reductions with treatment (-68%). Reproducibility (r) was the lowest for the Weinmann function (r = -49.7%) with the other AIFs ranging from r -27.8 to r -39.2%. Using the best performing AIF is essential to maximise the utility of quantitative DCE-MRI parameters in predicting response to NAC treatment. Applying our criteria the Modified Fritz-Hansen and Cosine Bolus approximated Parker AIF models performed best. The Fritz-Hansen and biexponential approximated Parker AIFs performed less well and the Weinmann and femoral artery AIFs are not recommended. We demonstrate that using the most appropriate Arterial Input Function (AIF) can aid successful prediction of response to neoadjuvant chemotherapy in breast cancer.
- Open Access
- 20 March 2015
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (4) , 368-369
Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors
This open-label phase I dose-escalation study investigated the safety, efficacy, pharmacokinetics (PK), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) effects of the oral angiokinase inhibitor nintedanib in patients with advanced solid tumors. Nintedanib was administered once daily continuously, starting at 100 mg and later amended to allow evaluation of 250 mg b.i.d. The primary endpoint was maximum tolerated dose (MTD). DCE-MRI studies were performed at baseline and on days 2 and 28. Fifty-one patients received nintedanib 100–450 mg once daily (n = 40) or 250 mg b.i.d. (n = 11). Asymptomatic reversible liver enzyme elevations (grade 3) were dose limiting in 2 of 5 patients at 450 mg once daily. At 250 mg b.i.d., 2 of 11 patients experienced dose-limiting toxicity (grade 3 liver enzyme elevation and gastrointestinal symptoms). Common toxicities included fatigue, diarrhea, nausea, vomiting, and abdominal pain (mainly grade ≤2). Among 45 patients, 22 (49%) achieved stable disease; 7 remained on treatment for >6 months. DCE-MRI of target lesions revealed effects in some patients at 200 and ≥400 mg once daily. Nintedanib is well tolerated by patients with advanced solid malignancies, with MTD defined as 250 mg b.i.d., and can induce changes in DCE-MRI. Disease stabilization >6 months was observed in 7 of 51 patients.
- 20 March 2015
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (4) , 368-369
Open AccessPhase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors
This open-label phase I dose-escalation study investigated the safety, efficacy, pharmacokinetics (PK), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) effects of the oral angiokinase inhibitor nintedanib in patients with advanced solid tumors. Nintedanib was administered once daily continuously, starting at 100 mg and later amended to allow evaluation of 250 mg b.i.d. The primary endpoint was maximum tolerated dose (MTD). DCE-MRI studies were performed at baseline and on days 2 and 28. Fifty-one patients received nintedanib 100–450 mg once daily (n = 40) or 250 mg b.i.d. (n = 11). Asymptomatic reversible liver enzyme elevations (grade 3) were dose limiting in 2 of 5 patients at 450 mg once daily. At 250 mg b.i.d., 2 of 11 patients experienced dose-limiting toxicity (grade 3 liver enzyme elevation and gastrointestinal symptoms). Common toxicities included fatigue, diarrhea, nausea, vomiting, and abdominal pain (mainly grade ≤2). Among 45 patients, 22 (49%) achieved stable disease; 7 remained on treatment for >6 months. DCE-MRI of target lesions revealed effects in some patients at 200 and ≥400 mg once daily. Nintedanib is well tolerated by patients with advanced solid malignancies, with MTD defined as 250 mg b.i.d., and can induce changes in DCE-MRI. Disease stabilization >6 months was observed in 7 of 51 patients.
- 17 August 2014
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 147 (2) , 335-343
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?
Quantitative DCE-MRI parameters including Ktrans (transfer constant min−1) can predict both response and outcome in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Quantitative methods are time-consuming to calculate, requiring expensive software and interpretive expertise. For diagnostic purposes, signal intensity–time curves (SITCs) are used for tissue characterisation. In this study, we compare the ability of NAC-related changes in SITCs with Ktrans to predict response and outcomes. 73 women with primary breast cancer underwent DCE-MRI studies before and after two cycles of NAC. Patients received anthracycline and/or docetaxel-based chemotherapy. At completion of NAC, patients had local treatment with surgery & radiotherapy and further systemic treatments. SITCs for paired DCE-MRI studies were visually scored using a five-curve type classification schema encompassing wash-in and wash-out phases and correlated with Ktrans values and to the endpoints of pathological response, OS and DFS. 58 paired patients studies were evaluable. The median size by MRI measurement for 52 tumours was 38 mm (range 17–86 mm) at baseline and 26 mm (range 10–85 mm) after two cycles of NAC. Median baseline Ktrans (min−1) was 0.214 (range 0.085–0.469), and post-two cycles of NAC was 0.128 (range 0.013–0.603). SITC shapes were significantly related to Ktrans values both before (χ 2 = 43.3, P = 0.000) and after two cycles of NAC (χ 2 = 60.5, P = 0.000). Changes in curve shapes were significantly related to changes in Ktrans (χ 2 = 53.5, P = 0.000). Changes in curve shape were significantly correlated with clinical (P = 0.005) and pathological response (P = 0.005). Reductions in curve shape of ≥1 point were significant for overall improved survival using Kaplan–Meier analysis with a 5-year OS of 80.9 versus 68.6 % (P = 0.048). SITCs require no special software to generate and provide a useful method of assessing the effectiveness of NAC for primary breast cancer.
- 17 August 2014
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 147 (2) , 335-343
Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate?
Quantitative DCE-MRI parameters including Ktrans (transfer constant min−1) can predict both response and outcome in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Quantitative methods are time-consuming to calculate, requiring expensive software and interpretive expertise. For diagnostic purposes, signal intensity–time curves (SITCs) are used for tissue characterisation. In this study, we compare the ability of NAC-related changes in SITCs with Ktrans to predict response and outcomes. 73 women with primary breast cancer underwent DCE-MRI studies before and after two cycles of NAC. Patients received anthracycline and/or docetaxel-based chemotherapy. At completion of NAC, patients had local treatment with surgery & radiotherapy and further systemic treatments. SITCs for paired DCE-MRI studies were visually scored using a five-curve type classification schema encompassing wash-in and wash-out phases and correlated with Ktrans values and to the endpoints of pathological response, OS and DFS. 58 paired patients studies were evaluable. The median size by MRI measurement for 52 tumours was 38 mm (range 17–86 mm) at baseline and 26 mm (range 10–85 mm) after two cycles of NAC. Median baseline Ktrans (min−1) was 0.214 (range 0.085–0.469), and post-two cycles of NAC was 0.128 (range 0.013–0.603). SITC shapes were significantly related to Ktrans values both before (χ 2 = 43.3, P = 0.000) and after two cycles of NAC (χ 2 = 60.5, P = 0.000). Changes in curve shapes were significantly related to changes in Ktrans (χ 2 = 53.5, P = 0.000). Changes in curve shape were significantly correlated with clinical (P = 0.005) and pathological response (P = 0.005). Reductions in curve shape of ≥1 point were significant for overall improved survival using Kaplan–Meier analysis with a 5-year OS of 80.9 versus 68.6 % (P = 0.048). SITCs require no special software to generate and provide a useful method of assessing the effectiveness of NAC for primary breast cancer.